NAD+ hydrolysis catalyzed by SelO is required for mitochondrial homeostasis
2026 Cell study of an endogenous mitochondrial NAD+ reaction. This is mechanistic evidence, not a test of this catalog material.
Read publicationResearch Library
Recent scientific literature, with publication year and evidence type. Blend references describe components or different formulations unless explicitly stated.
References checked September 9, 2026. Recent relevant publications are prioritized. Research does not validate EULIX materials or batches.
Growth hormone-releasing hormone, cognition and brain connectivity
2026 placebo-controlled pilot trial of tesamorelin in 22 adults. It did not test ipamorelin or the 13 + 3 mg blend.
Read publicationTRIUMPH: tesamorelin as an adjunct to exercise
July 2026 protocol in people living with HIV. A protocol describes planned research, not completed results; this is not a study of the blend.
Read publicationRetatrutide in type 2 diabetes — TRANSCEND-T2D-1
Clinical study of glycaemic control. Published in The Lancet, June 2026.
Read publicationTirzepatide versus intensified conventional care over two years
Study in early type 2 diabetes. Annals of Internal Medicine, July 2026.
Read publicationWeight maintenance — SURMOUNT-MAINTAIN
Maintenance study in people with obesity. The Lancet, June 2026.
Read publicationMOTS-c and interferon-linked host defense
Research on endogenous MOTS-c and immune signaling, including human monocytes. eLife, August 2026.
Read publicationMOTS-c and muscle mitochondrial bioenergetics
Investigation of PGC-1α / AMPK-dependent mechanisms. Free Radical Biology and Medicine, March 2026.
Read publicationTesamorelin: body composition, hepatic fat and safety
2026 synthesis of five randomized trials; a new analysis of earlier studies, not a new trial.
Read publicationInjectable peptides: current orthopaedic research context
January 2026 review discussing CJC-1295 / ipamorelin among other peptides. It does not validate this no-DAC formulation or establish clinical benefit.
Read publicationGHK-Cu, mitochondrial function and stress-response pathways
Study in C. elegans, published May 2026. Component evidence only; not a study of GLOW.
Read publicationKPV, adipogenesis and lipid signaling
Cellular and mouse-model research, published August 2026. Not a study of KLOW.
Read publicationInflammation-responsive peptide delivery systems
January 2026 study of an engineered delivery strategy. It does not establish the properties of unmodified KPV or the KLOW blend.
Read publicationTesamorelin and neurocognitive impairment in people with HIV
Six-month open-label clinical study in a defined population. Published June 2025.
Read publicationGHK-Cu-loaded hydrogel for wound research
A different hydrogel formulation studied in 2025. Its findings cannot be transferred to the GLOW blend.
Read publication